Filing Flows › Twist Bioscience (TWST) › Q2 FY26 › vs Q1 FY26
Twist Bioscience (TWST) Q2 FY26 vs Q1 FY26 (quarter over quarter)
Twist Bioscience's revenue rose $7.0M (+7%) from $104M in Q1 FY26 to $111M in Q2 FY26. The biggest changes: NGS applications +$4.8M (+9%); DNA synthesis and protein solutions +$2.2M (+4%).
Twist Bioscience, Q2 FY26: revenue $111M (+19% year over year), operating margin -41.4%, net loss $44.0M, operating cash flow −$17.6M. The chart draws each line against Q1 FY26, the increases inside each band.
Every line
| Line | Q2 FY26 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| NGS applications | $57.4M | $52.6M | $4.8M | +9% |
| DNA synthesis and protein solutions | $53.3M | $51.1M | $2.2M | +4% |
| Revenue | $111M | $104M | $7.0M | +7% |
| Other income, net | $1.9M | $2.6M | −$761K | -29% |
| Net loss | $44.0M | $30.5M | $13.5M | +44% |
| Costs & expenses | $157M | $137M | $19.8M | +14% |
| Operating costs | $157M | $137M | $20.0M | +15% |
| Income tax | $43K | $253K | −$210K | -83% |
| Cost of revenue | $53.6M | $49.7M | $3.9M | +8% |
| Research & development | $19.7M | $17.1M | $2.6M | +15% |
| SG&A | $76.1M | $69.7M | $6.3M | +9% |
| Operating cash sources | $44.0M | $30.5M | $13.5M | +44% |
| Depreciation & amortization | $6.4M | $6.2M | $220K | +4% |
| Share-based compensation | $18.9M | $13.3M | $5.7M | +43% |
| Working capital & other | $1.1M | −$13.8M | $14.9M | — |
| Cash used in operations | $17.6M | $24.8M | −$7.3M | -29% |
| Net loss absorbed | $44.0M | $30.5M | $13.5M | +44% |
Questions
How much did Twist Bioscience's revenue grow quarter over quarter in Q2 FY26?
Twist Bioscience's revenue rose $7.0M (+7%) from $104M in Q1 FY26 to $111M in Q2 FY26.
What drove Twist Bioscience's revenue change in Q2 FY26?
NGS applications +$4.8M (+9%); DNA synthesis and protein solutions +$2.2M (+4%).